Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
ceftriaxone (ceftriaxone sodium)
Arpimed LLC
J01DD04
ceftriaxone (ceftriaxone sodium)
500mg
powder for solution for injection/infusion
(10) glass vial
Prescription
Registered
2016-12-26
SUMMARY PRODUCT CHARACTERISTIC (SPC) CEFTRIAXONE 500 MG, powder for solution for i/m, i/v injection and i/v infusion CEFTRIAXONE 1000 MG, powder for solution for i/m, i/v injection and i/v infusion 1. NAME OF THE MEDICINAL PRODUCT 1.1 TRADE NAME – Ceftriaxone 500 mg, Ceftriaxone 1000 mg 1.2 INTERNATIONAL NON-PROPERTY NAME – Ceftriaxone 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 500 mg vial contains: _ACTIVE INGREDIENT_: ceftriaxone (as sodium salt) – 500 mg. Each 1000 mg vial contains: _ACTIVE INGREDIENT_: ceftriaxone (as sodium salt) – 1000 mg. _For a full list of excipients, see section 6.1._ 3. PHARMACEUTICAL FORM Ceftriaxone 500 mg, powder for solution for i/m, i/v injection and i/v infusion Powder for solution for i/m, i/v injection and i/v infusion. White to yellowish-orange crystalline powder. Ceftriaxone 1000 mg, powder for solution for i/m, i/v injection and i/v infusion Powder for solution for i/m, i/v injection and i/v infusion. White to yellowish-orange crystalline powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ceftriaxone is indicated for the treatment of the following infections in adults and children including term neonates (from birth): Bacterial Meningitis Community acquired pneumonia Hospital acquired pneumonia Acute otitis media Intra-abdominal infections Complicated urinary tract infections (including pyelonephritis) Infections of bones and joints Complicated skin and soft tissue infections Gonorrhoea Syphilis Bacterial endocarditis Ceftriaxone may be used: For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age. For Pre-operative prophylaxis of surgical site infections In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, Read the complete document